Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells 10,000 Shares of Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the transaction, the insider directly owned 139,025 shares in the company, valued at approximately $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Mark Schoenberg also recently made the following trade(s):

• On Monday, September 8th, Mark Schoenberg sold 871 shares of Urogen Pharma stock. The stock was sold at an average price of $19.11, for a total transaction of $16,644.81.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN traded down $0.06 during trading on Thursday, reaching $25.21. The stock had a trading volume of 483,271 shares, compared to its average volume of 1,454,749. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $26.28. The firm’s fifty day moving average is $19.37 and its 200 day moving average is $15.86. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -7.30 and a beta of 1.06.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. The business had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. On average, research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of research analyst reports. Piper Sandler assumed coverage on Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a report on Monday, October 27th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Urogen Pharma presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Hedge Funds Weigh In On Urogen Pharma

Large investors have recently added to or reduced their stakes in the business. Allianz Asset Management GmbH purchased a new position in Urogen Pharma during the second quarter worth about $203,000. Bender Robert & Associates bought a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $475,000. Truist Financial Corp purchased a new position in shares of Urogen Pharma in the 2nd quarter worth approximately $423,000. Nuveen LLC bought a new position in shares of Urogen Pharma in the first quarter valued at approximately $1,028,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Urogen Pharma during the first quarter valued at approximately $194,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.